RxDoctor Payments Data

Carlos Giraldo, MD

Advanced Heart Failure and Transplant Cardiology · McAllen, TXNPI 1891892436

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $21,505 of the $33,977 with a category attached, or 63.3%. 33 manufacturers reported payments, led by Novartis at 41.4% of the total. Reporting peaked in 2019 at $19,315 and has fallen 91.8% since, to $1,576 in 2025.

$33,977in general payments, 2019–2025

Across 276 payments — averaging $123.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$14K
  • Boehringer Ingelheim$6K
  • Abiomed$3K
  • Lilly USA, LLC$3K
  • Edwards Lifesciences$3K
  • Boston Scientific$2K
  • plus $4K from 27 others

What the payments were for

  • Speaking & faculty fees$21,50563%
  • Travel & lodging$5,07515%
  • Food & beverage$7,37622%
  • Education$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,977 in reported general payments places this provider in the 65th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.

See all advanced heart failure and transplant cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$113,757
Medicare patients
351
Services billed
1,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan382$497,812
EliquisApixaban287$327,588
FarxigaDapagliflozin Propanediol224$228,702
XareltoRivaroxaban84$123,765
JardianceEmpagliflozin100$106,544
BrilintaTicagrelor77$64,255
VascepaIcosapent Ethyl42$30,262
Repatha PushtronexEvolocumab37$27,476
Ranolazine ErRanolazine220$25,538
Repatha SyringeEvolocumab27$15,596
DapagliflozinDapagliflozin Propanediol13$8,327
Metoprolol Succinate576$7,566
Atorvastatin Calcium786$7,449
Repatha SureclickEvolocumab11$7,310
Bumetanide119$5,329

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$14,055$497,812382 claims
PfizerEliquis$132$327,588287 claims
AstraZenecaFarxiga, Brilinta$40$292,957301 claims
Johnson & JohnsonXarelto$626$123,76584 claims
Boehringer IngelheimJardiance$6,061$106,544100 claims
Arbor Pharmaceuticals, Inc.Edarbi$15$3,16912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 75 advanced heart failure and transplant cardiology providers in Texas.

Other advanced heart failure and transplant cardiology in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →